EU Decision for Translarna Has Positive Read Through for Sarepta (SRPT) - Credit Suisse

Credit Suisse analyst Alethia Young said the CHMP decision to leave PTC's DMD drug Translarna with conditional approval on market in Europe is a positive read-through for Sarepta's (NASDAQ: SRPT) potential filing in the EU.

"At 100% probability of success, EU sales are worth $26/sh to our valuation", the analyst said.

The analyst maintained an Outperform rating and price target of $41 on SRPT.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $39.52 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Comcast Corp (CMCSA) PT Lowered to $48 at Pivotal Research
• Merck (MRK) PT Raised to $143 at Truist Securities